A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This was a Phase II, open-label, single-arm, single-stage, multicenter trial in patients with
relapsed non-small cell lung cancer (NSCLC), with the objective of assessing the activity of
the combination of erlotinib and pertuzumab on the basis of the endpoint of FDG-PET response
rate.